Shares of DBV Technologies (NASDAQ:DBVT) hit a new 52-week low on Tuesday . The stock traded as low as $20.00 and last traded at $20.31, with a volume of 2187 shares trading hands. The stock had previously closed at $20.07.
Several brokerages recently weighed in on DBVT. BidaskClub raised DBV Technologies from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 16th. Zacks Investment Research lowered DBV Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 27th. Deutsche Bank set a $33.00 target price on DBV Technologies and gave the company a “buy” rating in a report on Tuesday, March 27th. Finally, ValuEngine raised DBV Technologies from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. DBV Technologies presently has an average rating of “Hold” and a consensus target price of $46.00.
Get DBV Technologies alerts:
The firm has a market cap of $1.16 billion, a P/E ratio of -6.03 and a beta of 0.99. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 0.01.
Large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in shares of DBV Technologies by 20.2% during the fourth quarter. Geode Capital Management LLC now owns 20,833 shares of the company’s stock valued at $512,000 after purchasing an additional 3,499 shares during the last quarter. Bailard Inc. bought a new position in shares of DBV Technologies during the first quarter valued at approximately $1,084,000. Candriam Luxembourg S.C.A. bought a new position in shares of DBV Technologies during the fourth quarter valued at approximately $1,230,000. OLD Mission Capital LLC grew its holdings in shares of DBV Technologies by 498.5% during the fourth quarter. OLD Mission Capital LLC now owns 50,875 shares of the company’s stock valued at $1,252,000 after purchasing an additional 42,374 shares during the last quarter. Finally, Hudson Bay Capital Management LP grew its holdings in shares of DBV Technologies by 500.0% during the fourth quarter. Hudson Bay Capital Management LP now owns 60,000 shares of the company’s stock valued at $1,476,000 after purchasing an additional 50,000 shares during the last quarter. 45.14% of the stock is owned by institutional investors.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
